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Abstract
Characterizing a patient’s progression through stages of sepsis is critical for en-
abling risk stratification and adaptive, personalized treatment. However, commonly
used sepsis diagnostic criteria fail to account for significant underlying heterogene-
ity, both between patients as well as over time in a single patient. We introduce
a hidden Markov model of sepsis progression that explicitly accounts for patient
heterogeneity. Benchmarked against two sepsis diagnostic criteria, the model
provides a useful tool to uncover a patient’s latent sepsis trajectory and to identify
high-risk patients in whom more aggressive therapy may be indicated.
1 Introduction
Sepsis is a dysregulated immune response to infection, accounting for nearly 50% of all hospital
deaths and $15 billion in United States healthcare costs [1]. Understanding a patient’s progression
through stages of sepsis is a prerequisite for effective risk stratification and adaptive, personalized
treatment.
Hidden Markov models (HMMs) are a popular technique for modeling disease progression [2].
Early efforts on modeling sepsis progression based on Markov models [3, 4] consider patients as
a homogeneous group. However, septic patients’ presentation of the condition and response to
treatment are often characterized by significant heterogeneity both between patients and over time in
a single patient [5]. Moreover, current clinical diagnostic criteria (e.g. sepsis-1 criteria [6, 7] and
quick sequential organ failure assessment (qSOFA) [8]) only take into account levels (not variability)
of a few vital signs—typically at a single time point—without considering the past status of the
patient.
We introduce a discrete-time HMM to analyze patient progression through sepsis. Each discrete time
step is associated with five vital signs: systolic blood pressure, diastolic blood pressure, heart rate,
respiratory rate, and temperature. We account for patient heterogeneity to determine state transition
probabilities, incorporating patient age and two composite measures of illness as covariates. We
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Figure 1: Sepsis progression Markov process. Latent states S1, S2, and S3 represent increasing
severity. Discharged (G) and death (D) are absorbing states.
leverage a retrospective cohort of 25,000 patients with suspected or confirmed infection, a subset of
the Kaiser Permanente Northern California dataset [1].
2 Model specification
The hidden Markov process is summarized in Fig. 1. It comprises five states: discharged (G), three
latent states of increasing severity (S1, S2, and S3), and death (D). Both G and D are absorbing
states and are observed. Transition probabilities are based on a proportional hazards model: for patient
i, three covariates (age, acute physiology score (LAPS2), and chronic disease burden score (COPS2)),
denoted c(i), determine baseline risk. Global parameters β, λk, and γk (k ∈ {S1, S2, S3}) control
the balance of improving from state k (i.e. moving left in Fig. 1), worsening from state k (moving
right), or remaining in state k. The transition probability matrix for patient i is:

G S1 S2 S3 D
G 1 0 0 0 0
S1 γ1P1 (1− γ1)P1 1− P1 0 0
S2 0 γ2P2 (1− γ2)P2 1− P2 0
S3 0 0 γ3P3 (1− γ3)P3 1− P3
D 0 0 0 0 1
,
where Pk ≡ λk exp(−β>c(i)).
Transient states (S1, S2, and S3) are associated with five patient vital signs, denoted x(i)t for patient
i at time interval t. Vital signs were pre-processed to occur at synchronous six-hour time intervals.
Given a latent state k ∈ {S1, S2, S3}, the emission probability for a patient’s five vital signs are
modeled as normally distributed with mean vector µk and a diagonal covariance matrix Σk. Since
states G and D are observed, they are not associated with vital signs.
3 Results and Discussion
3.1 Model inference
We implemented a Metropolis-Hastings-within Gibbs sampler. Latent states (z(i)t ), healing parameters
(γk), and emission means (µk) and covariance matrices (Σk) are inferred with Gibbs updates. (We
omit derivations for brevity.) We placed a discrete uniform prior on z(i)t , a U(0, 1) prior on γk, a
flat Inv-Gamma(0.001, 1000) prior on diagonal elements in Σk, and normal priors on entries in µk
for which posterior distributions were insensitive to prior hyperparameter choices. The remaining
parameters, β and λk, were inferred with Metropolis-Hastings updates. We placed an improper
Gamma(0, 0) prior for each element of β and a Beta(100, 2) prior for λk.
We estimated all model parameters on a dataset of 20,000 patient hospitalization episodes. The
sampler generated 10,000 samples, by which point the chains were well-mixed. The last 2,000
samples were used to construct posterior distributions. We estimated the marginal maximum a
posteriori (MAP) value of each continuously valued parameter by applying a kernel density estimate
to the posterior samples of that parameter and estimating its mode. MAP estimates for emission
distribution means and standard deviations are shown in Table 1.
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Table 1: Marginal maximum a posteriori estimates for mean and standard deviation of emission
distributions for each vital sign and from each latent state.
Latent state
Vital sign S1 S2 S3
Systolic blood pressure (mm Hg) 118.6± 15.1 143.4± 16.3 116.4± 17.5
Diastolic blood pressure (mm Hg) 63.4± 9.3 77.2± 10.0 62.7± 11.2
Heart rate (min−1) 76.7± 12.1 83.3± 14.5 95.6± 16.4
Respiratory rate (min−1) 18.7± 1.6 19.1± 1.9 21.1± 4.9
Temperature (◦F) 98.0± 0.8 98.1± 0.8 98.6± 1.3
3.2 Model validation
For model validation and subsequent analyses, we leveraged two commonly used clinical sepsis
diagnostic criteria. Firstly, an early consensus definition developed sepsis criteria (later termed
"sepsis-1") based primarily on patient vital signs that was used for several decades [6, 7]. Sepsis-1
criteria are defined as bacterial infection plus two or more of the following systemic inflammatory
response syndrome (SIRS) conditions: (1) heart rate > 90 min−1, (2) respiratory rate > 20 min−1
or PaCO2 < 32 mm Hg, (3) temperature < 96.8 ◦F or temperature > 100.4 ◦F, and (4) white blood
cell count > 12,000/mm3 or < 4,000/mm3 or >10% immature bands. Note that the bacterial infection
criteria is met for all patients in the dataset. Secondly, a more recent consensus sepsis definition
involves a sequential organ failure assessment, or SOFA score, based primarily on laboratory test
results [8]. A simplified version of this assessment, called "quick SOFA" or qSOFA, includes two
vital signs (systolic blood pressure ≤ 100 mm Hg, respiratory rate ≥ 22) that can be directly applied
to our dataset at any time point.
We applied the vital sign portions of sepsis-1 and qSOFA criteria to each time point for all patients,
resulting in segments that indicate when diagnostic criteria are met. To validate the model, we
assessed overlaps between the inferred S3 segments of each patient and segments indicated by the
two diagnostic criteria. For both sepsis-1 and qSOFA criteria, the presence (or absence) of sepsis
diagnosis tended to increase (or decrease) with increasing severity of the HMM states. We also note
that inferred emission means from state S3 are consistent with vital sign values in sepsis-1 criteria.
3.3 Mortality risk analysis
The HMM’s most severe state (S3) provides clinical utility in mortality risk analysis. To assess
the ability of the S3 state to identify patients at high risk of mortality during hospitalization, we
first inferred the latent state trajectories of a held-out 5,000-patient dataset. For this dataset, global
parameters were fixed to the previously found MAP estimates, and the HMM was not provided with
patient outcomes. To compare the ability of sepsis-1 criteria, qSOFA criteria, and the S3 state to
distinguish between discharged and deceased patients, for each patient we calculated the proportion
of time points for which sepsis-1 or qSOFA criteria were met, or for which the predicted state was S3.
We then plotted these distributions, conditioned on patient outcome (Fig. 2). The Jensen-Shannon
divergence for each resulting distribution pair was 0.168 for sepsis-1 criteria, 0.097 for qSOFA
criteria, and 0.186 for the S3 state, indicating that the inferred S3 state is more discriminative of the
underlying risk state of the patient.
3.4 Sepsis trajectory analysis
Visualizing patient trajectories provides insights into underlying physiological patterns. We overlay
a patient’s vital signs with their predicted (MAP estimate) latent state for each time interval. Four
characteristic trajectories are shown in Fig. 3. In contrast to the HMM’s S3 state, sepsis-1 and/or
qSOFA criteria often over-predict sepsis for a patient who is ultimately discharged (Fig. 3A), or even
predict sepsis at time of discharge (Fig. 3B). Conversely, both criteria can miss diagnoses for the
entire trajectory of patients who die (Fig. 3D). The Markovian nature of the HMM also provides
a degree of temporal smoothing to the state trajectory, whereas sepsis-1 and qSOFA criteria can
repeatedly alternate diagnoses within a short timeframe, as in Fig. 3B-C.
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Figure 2: Distributions over each patient’s fraction of hospitalization duration for which sepsis-1
(A) or qSOFA (B) criteria were met, or for which the predicted state was S3 (C), conditioned upon
patient outcome. Distributions are normalized to have unit area.
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Figure 3: Characteristic state trajectories for four patients. Time intervals are colored according to
the marginal maximum a posteriori latent state (green = S1, blue = S2, red = S3). Five vital sign
time series are overlaid: systolic blood pressure (mm Hg), diastolic blood pressure (mm Hg), heart
rate (min−1), respiratory rate (min−1), and temperature (◦F). Two sets of bars (black or yellow) along
the top of the trajectory indicate time segments for which sepsis-1 (black bar) or qSOFA (yellow bar)
criteria diagnose the patient as septic. For A and B, the patient was discharged; for C and D, the
patient died.
4
Thus, while sepsis-1 and qSOFA criteria may prove useful in an early phase of hospitalization
as a trigger for clinical action, they have limited utility for representing the dynamic state of a
patient’s clinical course. Our HMM addresses these limitations by modeling temporal dependence
and incorporating patient-specific features, allowing for adaptive, personalized characterization of
patients’ physiologic states within a trajectory toward recovery or deterioration.
4 Conclusion
This study demonstrates the utility in using HMMs to provide insight into a patient’s underlying
physiological trajectory, which may be used to inform clinical decisions. Including additional
physiologic, laboratory, and treatment data in such models will likely improve the identification of
high-risk patients in whom more aggressive therapy is indicated as well as low-risk patients in whom
hospital discharge is indicated.
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